Brintellix - Instructions For Use, Indications, Doses

Table of contents:

Brintellix - Instructions For Use, Indications, Doses
Brintellix - Instructions For Use, Indications, Doses

Video: Brintellix - Instructions For Use, Indications, Doses

Video: Brintellix - Instructions For Use, Indications, Doses
Video: What is Brintellix? 2024, September
Anonim

Brintellix

Instructions for use:

  1. 1. Release form and composition
  2. 2. Indications for use
  3. 3. Contraindications
  4. 4. Method of application and dosage
  5. 5. Side effects
  6. 6. Special instructions
  7. 7. Drug interactions
  8. 8. Terms and conditions of storage

Prices in online pharmacies:

from 1693 rub.

Buy

Film-coated tablets, Brintellix
Film-coated tablets, Brintellix

Brintellix is an antidepressant.

Release form and composition

Dosage form - film-coated tablets:

  • 5 mg: almond-shaped, pink, embossed with TL on one side, number 5 on the other;
  • 10 mg: almond-shaped, light yellow, embossed TL on one side, “10” on the other;
  • 15 mg: almond-shaped, light orange, embossed with TL on one side, “15” on the other;
  • 20 mg: almond-shaped, brownish red, embossed with TL on one side and “20” on the other.

Packing of tablets: 14 pcs. in blister packs (blisters), in a cardboard box 1 or 2 packages.

Active ingredient: vortioxetine (in the form of hydrobromide), its content in 1 tablet is 5, 10, 15 or 20 mg.

Auxiliary components: mannitol, hyprolose, magnesium stearate, sodium carboxymethyl starch (type A), microcrystalline cellulose.

Film casing composition:

  • tablets 5 mg: Opadrai pink [titanium dioxide (E171), macrogol 400, hypromellose, iron dye red oxide (E172)];
  • tablets 10 mg: Opadry yellow [titanium dioxide (E171), macrogol 400, hypromellose, iron dye yellow oxide (E172)];
  • tablets 15 mg: Opadry orange [titanium dioxide (E171), macrogol 400, hypromellose, dye iron oxide red (E172) and iron oxide yellow (E172)];
  • tablets 20 mg: Opadrai red [titanium dioxide (E171), macrogol 400, hypromellose, iron dye red oxide (E172)].

Indications for use

Brintellix is used to treat major depressive episodes.

Contraindications

  • age up to 18 years;
  • pregnancy and lactation;
  • simultaneous use with non-selective monoamine oxidase inhibitors (MAOIs) or selective MAO type A inhibitors;
  • hypersensitivity to any component of the drug.

Carefully:

  • a history of seizures;
  • mania and hypomania;
  • pronounced suicidal behavior;
  • pharmacologically uncontrolled epilepsy;
  • bleeding tendency;
  • severe renal and hepatic impairment;
  • cirrhosis of the liver;
  • elderly age;
  • the period of electroconvulsive therapy;
  • simultaneous use of drugs that reduce the threshold of convulsive readiness, MAO type B inhibitors (selegiline, rasagiline), oral anticoagulants and drugs that affect platelet function, St. John's wort, serotonergic drugs, tryptophan, lithium, drugs that can cause hyponatremia.

Method of administration and dosage

Brintellix is intended for oral administration. The tablets can be taken with or without food.

The initial and recommended therapeutic dose for adult patients under the age of 65 is 10 mg 1 time per day. Depending on the effectiveness and tolerability of the drug, the therapeutic dose can be reduced to a minimum of 5 mg per day, or increased to a maximum of 20 mg per day.

Elderly patients (over 65 years of age) should start therapy with a daily dose of 5 mg. The maximum allowable daily dose is 10 mg.

The duration of treatment is determined individually. After elimination of the symptoms of depression, it is recommended to take the drug for at least another 6 months in order to consolidate the achieved effect.

If strong inhibitors of the CYP2D6 isoenzyme (for example, bupropion, quinidine, fluoxetine or paroxetine) or broad-spectrum cytochrome P 450 inducers (for example, rifampicin, carbamazepine, phenytoin) are added to the therapy, a dose adjustment of Brintellix may be required.

Side effects

  • from the gastrointestinal tract: very often (≥ 1/10) - nausea; often (from ≥ 1/100 to <1/10) - constipation / diarrhea, vomiting;
  • from the skin and subcutaneous tissues: often - itching (including generalized); infrequently (from ≥ 1/1000 to <1/100) - night sweats;
  • from the side of the psyche: often - unusual dreams;
  • from the nervous system: often - dizziness; frequency unknown - serotonin syndrome;
  • from the side of the vessels: infrequently - hot flashes.

Adverse reactions usually occur within the first 2 weeks of treatment, are temporary and do not require Brintellix to be discontinued.

The side effect of nausea is more common in women than in men.

special instructions

Depression is associated with an increased risk of suicidal thoughts, self-harm, and suicidal behavior. This risk persists until the onset of pronounced remission, therefore, until the moment of significant improvement in the condition, patients should be under constant supervision. The same applies to individuals with a history of suicidal behavior.

Patients and their caregivers should be warned to seek immediate medical attention if signs of clinical deterioration, suicidal thoughts, or unusual behavioral changes appear.

At the end of therapy, the drug can be canceled at once, a gradual dose reduction is not required.

During therapy, one should refrain from drinking alcoholic beverages.

Brintellix does not affect or has very little effect on the speed of reactions and the ability to concentrate. However, caution is advised when driving and performing potentially hazardous work, especially at the beginning of treatment.

Drug interactions

  • lithium, tryptophan, serotonergic drugs, reversible and irreversible non-selective MAO inhibitors (including MAO A), irreversible non-selective MAO inhibitors (including MAO B): can lead to the development of serotonin syndrome;
  • St. John's wort: increases the risk of side effects, including serotonin syndrome;
  • drugs that lower the seizure threshold (for example, antidepressants and antipsychotics): a pronounced decrease in the seizure threshold is possible;
  • inhibitors of the isoenzyme CYP2D6, CYP3A4 and CYP2C9: an increase in the exposure of vortioxetine is possible;
  • inducers of cytochrome P 450: exposure of vortioxetine decreases.

The experience of using vortioxetine concomitantly with electroconvulsive therapy is insufficient, therefore, treatment should be carried out with caution.

Terms and conditions of storage

Keep out of reach of children at temperatures up to 25 ºС.

The shelf life is 3 years.

Brintellix: prices in online pharmacies

Drug name

Price

Pharmacy

Brintellix 5 mg film-coated tablets 28 pcs.

1693 RUB

Buy

Brintellix 10 mg film-coated tablets 28 pcs.

1985 RUB

Buy

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Recommended: